Bart Henderson

Bart Henderson is Chief Executive Officer of Wren. Bart brings extensive experience in company-building and developing innovative medicines. Previously he was an operating partner at Flagship Pioneering where he led the build-out of Harbinger Health, developing an early-stage cancer detection platform with leading-edge artificial intelligence and machine learning technologies. Prior to Flagship, he was CEO and co-founder of Torque (now Repertoire Immune Medicines) where, under his leadership, the company significantly advanced its cellular immunotherapy pipeline, initiating the company’s first clinical trial, receiving Fast Track designation from the FDA, and building a state-of-the-art manufacturing facility for Torque’s T cell immunotherapies. Bart was founder and president of Rhythm and its subsidiary Motus which together completed successful Phase II clinical trials for two metabolic products: setmelanotide which was granted Breakthrough Designation and is the first drug approved in the US for genetic obesity; and relamorelin which was acquired by Allergan (with Motus). He was a founding employee and chief business officer of Radius, where he built the pipeline and launched the first clinical trial for Tymlos®, now approved for the treatment of osteoporosis, and acquired Elascestrant, currently in phase 3 for the treatment of metastatic breast cancer. Previously, he was an entrepreneur-in-residence at MPM Capital. He led business development at Microbia (now Ironwood Pharmaceuticals) and was head of sales and marketing at Vertex which launched its first product and significantly expanded its pipeline during his tenure. Bart previously held marketing management positions at Amgen and Merck. Bart received an M.B.A. from Dartmouth’s Tuck School of Business and a B.A. from Amherst College.